Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE4
90 participants
INTERVENTIONAL
2019-02-25
2020-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Minocycline for Schizophrenia
NCT01809158
Proof of Concept Study of Cognitive Improvement in Patients With Schizophrenia
NCT00528905
Safety, Tolerability, and Pharmacokinetics Study of MK-8189 in Participants With Schizophrenia and Healthy Participants (MK-8189-011)
NCT04506905
The Study of Minocycline for Negative and Cognitive Symptoms in Schizophrenia
NCT01493622
Anti-Inflammatory Treatment of Schizophrenia
NCT01514682
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Patients will start the antipsychotic medication assigned by their treating physician. They will also be assigned randomly to the treatment arm. The study drug will be provided by the research team under the presentation of capsules containing Celecoxib 200 mg, Minocycline 100 mg or Placebo, and patients will be instructed to take one capsule every 12 hrs daily.
The patient will be reassessed with PANSS, PSP, and MCCB after completing 6 weeks of pharmacological treatment, type and dose of medication will be recorded and serum markers of inflammation will be determined again.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Celecoxib
Celecoxib 200 mg twice a day
Celecoxib 200mg
Will be administered for 6 weeks
Minocycline
Minocycline 100 mg twice a day
Minocycline 100mg
Will be administered for 6 weeks
Placebo
Placebo capsules twice a day
Placebo oral capsule
Will be administered for 6 weeks
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Celecoxib 200mg
Will be administered for 6 weeks
Placebo oral capsule
Will be administered for 6 weeks
Minocycline 100mg
Will be administered for 6 weeks
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients in their first psychotic episode or previously diagnosed
* No specific pharmacological treatment (antipsychotic at therapeutic doses in regular doses) in the previous two weeks.
* Have a responsible parent or guardian.
Exclusion Criteria
* Chronic somatic diseases, including autoimmune diseases
* Comorbidity with anorexia, substance use disorders
* Pregnancy
* Use of anti-inflammatory medications or antibiotics
12 Years
17 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hospital Psiquiatrico Infantil Dr. Juan N. Navarro, Mexico
OTHER_GOV
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hospital Psiquiatrico Infantil
Mexico City, Ni Ee.uu. Ni Canadá, Mexico
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
II3/02/0618
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.